Information  X 
Enter a valid email address

Valirx Plc (VAL) to reveal plans for growth and development at the Shares Investor Evening on 15th D

By BFN News | 01:06 PM | Friday 04 December, 2015


Valirx Plc (VAL)[VAL] will be presenting its performance in the past year as well as its plans for growth and development at the free-to-attend Shares investor evening in London on 15th December 2015. About Valirx Plc (VAL) Valirx Plc (VAL) is an oncology-focussed Biopharmaceutical Company, developing treatments and diagnostics. Technologies are selected by using rigorous clinical and commercial processes to address unmet market needs. Clinical lead product is VAL201, a peptide for prostate cancer with follow-on indications in ovarian and breast cancers and endometriosis. Product VAL401, is a small molecule reformulation for lung cancers. The Company�€?s proprietary technology platform, GeneICE, enables selective silencing of rebellious genes�€? inappropriate activity. VAL101, the first GeneICE therapeutic, targets and reduces expression of Bcl-2, implicated in about half of cancers. GeneICE extension to neurology and inflammatory diseases will follow. A novel diagnostic, the Nav3 system, detects pre-cancerous, cancerous and metastatic cells in tissue samples even before a tumour forms; indicating potential malignant formation. For more information, visit http://www.sharesmagazine.co.uk/events/event/shares-investor-evening-15-dec-15/presenting/ At 1:06pm: (LON:VAL) ValiRx PLC share price was -0.75p at 18p Story provided by StockMarketWire.com

a d v e r t i s e m e n t